Perfect summary TT, The market performance over the last year is...

First 64 Last

Share
Profile

Follow
raiizo

663 Posts.

103

12/11/17

16:29

Post #: 28715045
Share

Originally posted by tinyteddy ↑

Mr. Market knows there are lots of other players in this field. Some of them, at earlier stages of development, have done deals. Mr. Market wants to know is this company serious about doing a deal, or is it just using small scale research to feed an attractive story to keep raising funds to keep its execs employed forever. That's the question.
For those of you who think that's mercenary, it actually isn't. If the product is truly helpful, then it needs to be bought by a major and developed to a product. If Viralytics sits on it forever just to raise cash, they will deny it to the world.
Remember Hep C? Would you like to have a novel Hep C idea now? No, that wave has passed. But many smart companies sold their IP at great prices at the time, whether or not they ultimately made it to product.
Oncolytic viruses will be the same. It's time in the sun will be limited. These guys need to do a deal. Indeed should have done one in the last 12-18 months. So, it's either the product isn't good enough, or they don't want to/can't do a deal (i.e no skill, or deliberately asking too much). I think the latter. The R&D tax rebate means the money they raised mostly still sits in the bank. And they don't care about dilution because they protect themselves against that with options.

Expand

Perfect summary TT,

The market performance over the last year is a clear indication that most think the Board and Management are all too happy sitting on their dilution treasure chest whilst paying themselves exorbitantly and living the cruisy life.

My main hope is that the major funds on the register eventually have enough of the bull shit and force a move by VLA.

VLA Price at posting: 81.0¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply